A 12 month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of ranibizumab 0.5 mg on Cystoid, Spongy & Mixed OCT patterns secondary to Diabetic Macular Edema (DME)- LUCID

Trial Profile

A 12 month, open label, multi-center study to evaluate the efficacy and safety of intravitreal injections of ranibizumab 0.5 mg on Cystoid, Spongy & Mixed OCT patterns secondary to Diabetic Macular Edema (DME)- LUCID

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms LUCID
  • Most Recent Events

    • 18 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top